Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESPB With Ropivacaine for Postoperative Pain in Mastectomy
NCT07562945Not yet recruiting
- Sponsor
- Aldy
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Aldy. Primary endpoint: Postoperative Pain Intensity at 24 hours. Planned start May 2026; status: not yet recruiting.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07562945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562945.